Crestor Campaign Makes FDA Complain; "Clearly The Best" Given A Rest
This article was originally published in The Pink Sheet Daily
Executive Summary
An FDA "untitled" letter takes issue with AstraZeneca's presentation of comparative claims to other statins in an ad campaign that states Crestor is "clearly the best." This is the second ad division letter sent to AstraZeneca for Crestor promotions. AstraZeneca says the FDA-cited campaign concluded at the end of 2004.